251 related articles for article (PubMed ID: 10671494)
1. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene.
Heath RJ; Li J; Roland GE; Rock CO
J Biol Chem; 2000 Feb; 275(7):4654-9. PubMed ID: 10671494
[TBL] [Abstract][Full Text] [Related]
2. The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis.
Heath RJ; Su N; Murphy CK; Rock CO
J Biol Chem; 2000 Dec; 275(51):40128-33. PubMed ID: 11007778
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of triclosan inhibition of bacterial fatty acid synthesis.
Heath RJ; Rubin JR; Holland DR; Zhang E; Snow ME; Rock CO
J Biol Chem; 1999 Apr; 274(16):11110-4. PubMed ID: 10196195
[TBL] [Abstract][Full Text] [Related]
4. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene.
Marcinkeviciene J; Jiang W; Kopcho LM; Locke G; Luo Y; Copeland RA
Arch Biochem Biophys; 2001 Jun; 390(1):101-8. PubMed ID: 11368521
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; Payne DJ; Rittenhouse SF; Moore TD; DeWolf WE; Keller PM; Qiu X; Janson CA; Vaidya K; Fosberry AP; Smyth MG; Jaworski DD; Slater-Radosti C; Huffman WF
Bioorg Med Chem Lett; 2001 Sep; 11(17):2241-4. PubMed ID: 11527706
[TBL] [Abstract][Full Text] [Related]
6. Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus.
Xu H; Sullivan TJ; Sekiguchi J; Kirikae T; Ojima I; Stratton CF; Mao W; Rock FL; Alley MR; Johnson F; Walker SG; Tonge PJ
Biochemistry; 2008 Apr; 47(14):4228-36. PubMed ID: 18335995
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.
Hoang TT; Schweizer HP
J Bacteriol; 1999 Sep; 181(17):5489-97. PubMed ID: 10464225
[TBL] [Abstract][Full Text] [Related]
8. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
[TBL] [Abstract][Full Text] [Related]
9. Exploring the interaction energies for the binding of hydroxydiphenyl ethers to enoyl-acyl carrier protein reductases.
Muralidharan J; Suguna K; Surolia A; Surolia N
J Biomol Struct Dyn; 2003 Feb; 20(4):589-94. PubMed ID: 12529157
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
Sivaraman S; Sullivan TJ; Johnson F; Novichenok P; Cui G; Simmerling C; Tonge PJ
J Med Chem; 2004 Jan; 47(3):509-18. PubMed ID: 14736233
[TBL] [Abstract][Full Text] [Related]
12. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus.
Fan F; Yan K; Wallis NG; Reed S; Moore TD; Rittenhouse SF; DeWolf WE; Huang J; McDevitt D; Miller WH; Seefeld MA; Newlander KA; Jakas DR; Head MS; Payne DJ
Antimicrob Agents Chemother; 2002 Nov; 46(11):3343-7. PubMed ID: 12384334
[TBL] [Abstract][Full Text] [Related]
13. Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.
Massengo-Tiassé RP; Cronan JE
J Biol Chem; 2008 Jan; 283(3):1308-1316. PubMed ID: 18032386
[TBL] [Abstract][Full Text] [Related]
14. Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.
Kronenberger T; de Oliveira Fernades P; Drumond Franco I; Poso A; Gonçalves Maltarollo V
ChemMedChem; 2019 Dec; 14(23):1995-2004. PubMed ID: 31670463
[TBL] [Abstract][Full Text] [Related]
15. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).
Yao J; Maxwell JB; Rock CO
J Biol Chem; 2013 Dec; 288(51):36261-71. PubMed ID: 24189061
[TBL] [Abstract][Full Text] [Related]
16. Signature gene expression profile of triclosan-resistant Escherichia coli.
Yu BJ; Kim JA; Pan JG
J Antimicrob Chemother; 2010 Jun; 65(6):1171-7. PubMed ID: 20410062
[TBL] [Abstract][Full Text] [Related]
17. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
Heerding DA; Chan G; DeWolf WE; Fosberry AP; Janson CA; Jaworski DD; McManus E; Miller WH; Moore TD; Payne DJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Smith W; Takata DT; Vaidya KS; Yuan CC; Huffman WF
Bioorg Med Chem Lett; 2001 Aug; 11(16):2061-5. PubMed ID: 11514139
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs.
Sivaraman S; Zwahlen J; Bell AF; Hedstrom L; Tonge PJ
Biochemistry; 2003 Apr; 42(15):4406-13. PubMed ID: 12693936
[TBL] [Abstract][Full Text] [Related]
19. Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex.
Chang A; Schiebel J; Yu W; Bommineni GR; Pan P; Baxter MV; Khanna A; Sotriffer CA; Kisker C; Tonge PJ
Biochemistry; 2013 Jun; 52(24):4217-28. PubMed ID: 23697754
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by beta-lactamases.
Stone GW; Zhang Q; Castillo R; Doppalapudi VR; Bueno AR; Lee JY; Li Q; Sergeeva M; Khambatta G; Georgopapadakou NH
Antimicrob Agents Chemother; 2004 Feb; 48(2):477-83. PubMed ID: 14742198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
